- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2017
- Public Summary Document (PSD) July 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2017 PBAC Meeting - Word
Ocrelizumab – July 2017
Ocrelizumab: Solution concentrate for I.V. infusion 300 mg in 10 mL; Ocrevus®
Last updated
27 October 2017